Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation

Virology

Volumn 468, Issue , 2014, Pages 265-273

  Wang, Wenling ^a   Huang, Baoying ^a   Jiang, Tao ^a   Wang, Xiuping ^a   Qi, Xiangrong ^a   Tan, Wenjie ^a   Ruan, Li ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Al(OH)3; CpG; Influenza A virus; Nucleoprotein; Protective immunity; Protein subunit vaccines

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CPG 1826; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 4; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; ALUMINUM HYDROXIDE; NUCLEOPROTEIN; OLIGODEOXYRIBONUCLEOTIDE; PROTEIN SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; EMBRYO; ESCHERICHIA COLI; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A; ION EXCHANGE CHROMATOGRAPHY; MOUSE; NONHUMAN; VIRUS RESISTANCE; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN SUBUNIT;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION REGULATION, VIRAL; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; OLIGODEOXYRIBONUCLEOTIDES; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN SUBUNITS;

EID: 84907463199     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.08.008     Document Type: Article

References (69)

1. Adar Y., Singer Y., Levi R., Tzehoval E., Perk S., Banet-Noach C., Nagar S., Arnon R., Ben-Yedidia T. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009, 27:2099-2107.
2. Altmuller A., Fitch W.M., Scholtissek C. Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses. J. Gen. Virol. 1989, 70:2111-2119.
3. Antrobus R.D., Lillie P.J., Berthoud T.K., Spencer A.J., McLaren J.E., Ladell K., Lambe T., Milicic A., Price D.A., Hill A.V., Gilbert S.C. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 2012, 7:e48322.
4. Antrobus R.D., Coughlan L., Berthoud T.K., Dicks M.D., Hill A.V., Lambe T., Gilbert S.C. Clinical assessment of a novel recombinant simian adenovirus chadox1 as a vectored vaccine expressing conserved influenza A antigens. Mol. Ther. 2014, 22:668-674.
5. Ashraf S., Kong W., Wang S., Yang J., Curtiss R. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. Vaccine 2011, 29:3990-4002.
6. Atsmon J., Kate-Ilovitz E., Shaikevich D., Singer Y., Volokhov I., Haim K.Y., Ben-Yedidia T. Safety and immunogenicity of multimeric-001-a novel universal influenza vaccine. J. Clin. Immunol. 2012, 32:595-603.
7. Barefoot B.E., Sample C.J., Ramsburg E.A. Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin. Vaccine Immunol. 2009, 16:488-498.
8. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., Milicic A., Poyntz H.C., Lambe T., Fletcher H.A., Hill A.V., Gilbert S.C. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 2011, 52:1-7.
9. Bevan M.J. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 2004, 4:595-602.
10. Brewoo J.N., Powell T.D., Jones J.C., Gundlach N.A., Young G.R., Chu H., Das S.C., Partidos C.D., Stinchcomb D.T., Osorio J.E. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine 2013, 31:1848-1855.
11. Carragher D.M., Kaminski D.A., Moquin A., Hartson L., Randall T.D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 2008, 181:4168-4176.
12. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., Cameron D.W., Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 2004, 24:693-701.
13. Epstein S.L., Stack A., Misplon J.A., Lo C.Y., Mostowski H., Bennink J., Subbarao K. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ cytotoxic T lymphocytes: either CD4+ or CD8+ T cells can promote survival and recovery after challenge. Int. Immunol. 2000, 12:91-101.
14. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., Nabel G.J. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5401-5410.
15. Fedson D.S. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J. Public Health Policy 2005, 26:4-29.
16. Fu T.M., Guan L., Friedman A., Schofield T.L., Ulmer J.B., Liu M.A., Donnelly J.J. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J. Immunol. 1999, 162:4163-4170.
17. Gao X., Wang W., Li Y., Zhang S., Duan Y., Xing L., Zhao Z., Zhang P., Li Z., Li R., Wang X., Yang P. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. Antiviral Res. 2013, 98:4-11.
18. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
19. Gerhard W., Mozdzanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol. Rev. 1997, 159:95-103.
20. Grant E., Wu C., Chan K.F., Eckle S., Bharadwaj M., Zou Q.M., Kedzierska K., Chen W. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T-cell responses. Immunol. Cell Biol. 2013, 91:184-194.
21. Guo L., Zheng M., Ding Y., Li D., Yang Z., Wang H., Chen Q., Sui Z., Fang F., Chen Z. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch. Virol. 2010, 155:1765-1775.
22. Gupta K., Cooper C. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R D 2008, 9:137-145.
23. Haynes L., Szaba F.M., Eaton S.M., Kummer L.W., Lanthier P.A., Petell A.H., Duso D.K., Luo D., Lin J.S., Lefebvre J.S., Randall T.D., Johnson L.L., Kohlmeier J.E., Woodland D.L., Smiley S.T. Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections. J. Immunol. 2012, 189:4921-4929.
24. Hessel A., Savidis-Dacho H., Coulibaly S., Portsmouth D., Kreil T.R., Crowe B.A., Schwendinger M.G., Pilz A., Barrett P.N., Falkner F.G., Schafer B. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One 2014, 9:e88340.
25. Huang B., Wang W., Li R., Wang X., Jiang T., Qi X., Gao Y., Tan W., Ruan L. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol. J. 2012, 9:322.
26. Jamali A., Sabahi F., Bamdad T., Hashemi H., Mahboudi F., Kheiri M.T. A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model. Clin. Vaccine Immunol. 2010, 17:683-687.
27. Jameson J., Cruz J., Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998, 72:8682-8689.
28. Jameson J., Cruz J., Terajima M., Ennis F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J. Immunol. 1999, 162:7578-7583.
29. Jeon S.H., Ben-Yedidia T., Arnon R. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 2002, 20:2772-2780.
30. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., Lalor P., Leamy V., Vahle R., Luke C.J., Rolland A., Kaslow D.C., Smith L.R. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum. Vaccines 2007, 3:157-164.
31. Kheiri M.T., Jamali A., Shenagari M., Hashemi H., Sabahi F., Atyabi F., Saghiri R. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Antiviral Res. 2012, 95:229-236.
32. Kim S.H., Kim J.Y., Choi Y., Nguyen H.H., Song M.K., Chang J. Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PLoS One 2013, 8:e75460.
33. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., Smith L.R. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 2008, 197:1643-1652.
34. Lambe T., Carey J.B., Li Y., Spencer A.J., van Laarhoven A., Mullarkey C.E., Vrdoljak A., Moore A.C., Gilbert S.C. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci. Rep. 2013, 3:1443.
35. Lamere M.W., Moquin A., Lee F.E., Misra R.S., Blair P.J., Haynes L., Randall T.D., Lund F.E., Kaminski D.A. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 2011, 85:5027-5035.
36. Li Z., Gabbard J.D., Mooney A., Gao X., Chen Z., Place R.J., Tompkins S.M., He B. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses. J. Virol. 2013, 87:5985-5993.
37. Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., Hamill M., Peng Y., Blais M.E., Duncan C.J., Sheehy S.H., Havelock T., Faust S.N., Williams R.L., Gilbert A., Oxford J., Dong T., Hill A.V., Gilbert S.C. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 2012, 55:19-25.
38. Lo C.Y., Wu Z., Misplon J.A., Price G.E., Pappas C., Kong W.P., Tumpey T.M., Epstein S.L. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 2008, 26:2062-2072.
39. Luo J., Zheng D., Zhang W., Fang F., Wang H., Sun Y., Ding Y., Xu C., Chen Q., Zhang H., Huang D., Sun B., Chen Z. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. Virol. J. 2012, 9:286.
40. MacLeod M.K., David A., Jin N., Noges L., Wang J., Kappler J.W., Marrack P. Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One 2013, 8:e61775.
41. McMichael A.J., Gotch F.M., Noble G.R., Beare P.A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 1983, 309:13-17.
42. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J. Gen. Virol. 1986, 67:719-726.
43. Moraes T.J., Lin G.H., Wen T., Watts T.H. Incorporation of 4-1BB ligand into an adenovirus vaccine vector increases the number of functional antigen-specific CD8 T cells and enhances the duration of protection against influenza-induced respiratory disease. Vaccine 2011, 29:6301-6312.
44. Mullarkey C.E., Boyd A., van Laarhoven A., Lefevre E.A., Veronica Carr B., Baratelli M., Molesti E., Temperton N.J., Butter C., Charleston B., Lambe T., Gilbert S.C. Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine. Eur. J. Immunol. 2013, 43:1940-1952.
45. Nguyen H.H., Zemlin M., Ivanov I.I., Andrasi J., Zemlin C., Vu H.L., Schelonka R., Schroeder H.W., Mestecky J. Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire. J. Virol. 2007, 81:9331-9338.
46. Palese P. Making better influenza virus vaccines?. Emerg. Infect. Dis. 2006, 12:61-65.
47. Patterson D.P., Rynda-Apple A., Harmsen A.L., Harmsen A.G., Douglas T. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 2007, 7:3036-3044.
48. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Pappas C., Houser K.V., Tumpey T.M., Epstein S.L. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009, 27:6512-6521.
49. Price G.E., Soboleski M.R., Lo C.Y., Misplon J.A., Quirion M.R., Houser K.V., Pearce M.B., Pappas C., Tumpey T.M., Epstein S.L. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 2010, 5:e13162.
50. Rangel-Moreno J., Carragher D.M., Misra R.S., Kusser K., Hartson L., Moquin A., Lund F.E., Randall T.D. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J. Immunol. 2008, 180:454-463.
51. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009, 30:23-32.
52. Rohde J., Amann R., Rziha H.J. New orf virus (parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 Influenza A virus. PLoS One 2013, 8:e83802.
53. Saha S., Yoshida S., Ohba K., Matsui K., Matsuda T., Takeshita F., Umeda K., Tamura Y., Okuda K., Klinman D., Xin K.Q., Okuda K. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology 2006, 354:48-57.
54. Savard C., Laliberte-Gagne M.E., Babin C., Bolduc M., Guerin A., Drouin K., Forget M.A., Majeau N., Lapointe R., Leclerc D. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. Vaccine 2012, 30:2535-2542.
55. Sealy R., Surman S., Hurwitz L., Coleclough C. Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens. Immunology 2003, 108:431-439.
56. Shu L.L., Bean W.J., Webster R.G. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J. Virol. 1993, 67:2723-2729.
57. Sipo I., Knauf M., Fechner H., Poller W., Planz O., Kurth R., Norley S. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine 2011, 29:1690-1699.
58. Tamura S., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., Suzuki Y., Aizawa C., Kurata T. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol. 1996, 156:3892-3900.
59. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., Hogan R.J., Wu Z., Benton K.A., Tumpey T.M., Epstein S.L. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 2007, 13:426-435.
60. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27:3331-3334.
61. Ulmer J.B., Fu T.M., Deck R.R., Friedman A., Guan L., DeWitt C., Liu X., Wang S., Liu M.A., Donnelly J.J., Caulfield M.J. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 1998, 72:5648-5653.
62. Vitelli A., Quirion M.R., Lo C.Y., Misplon J.A., Grabowska A.K., Pierantoni A., Ammendola V., Price G.E., Soboleski M.R., Cortese R., Colloca S., Nicosia A., Epstein S.L. Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus. PLoS One 2013, 8:e55435.
63. Wang G., Zhou F., Buchy P., Zuo T., Hu H., Liu J., Song Y., Ding H., Tsai C., Chen Z., Zhang L., Deubel V., Zhou P. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin. J. Infect. Dis. 2014, 209:676-685.
64. Wang W., Huang B., Wang X., Tan W., Ruan L. Screening of enzyme-linked immunospot epitopes of influenza A virus nucleocapsid protein in BALB/c mice and studying on their relationship with cytolytic T lymphocytes epitopes. Chin. Lett. Biotechnol. 2008, 19:319-323.
65. Wang W., Huang B., Jiang T., Wang X., Qi X., Gao Y., Tan W., Ruan L. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli. PLoS One 2012, 7:e52488.
66. Wraith D.C., Vessey A.E., Askonas B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 1987, 68:433-440.
67. Xu K., Ling Z.Y., Sun L., Xu Y., Bian C., He Y., Lu W., Chen Z., Sun B. Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol. 2011, 24:45-56.
68. Yewdell J.W., Frank E., Gerhard W. Expression of influenza A virus antigen on the surface of infected P815 cells. J. Immunol. 1981, 126:1814-1819.
69. Zheng B., Zhang Y., He H., Marinova E., Switzer K., Wansley D., Mbawuike I., Han S. Rectification of age-associated deficiency in cytotoxic T cell response to influenza a virus by immunization with immune complexes. J. Immunol. 2007, 179:6153-6159.